title: Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report.
abstract: BACKGROUND
  The optimal duration of ixabepilone and capecitabine chemotherapy combination is currently not known and will most likely be patient-specific based on efficacy, toxicity, quality of life, and patient preference.
  
  
  METHODS
  We report an extremely long duration of chemotherapy with ixabepilone and capecitabine (42 cycles) in a patient with triple-negative metastatic breast cancer previously treated with anthracyclines and taxanes. Partial remission was achieved, and acceptable toxicity was observed.
  
  
  CONCLUSIONS
  This report adds to the pool of knowledge regarding the use of this important new metastatic breast cancer regimen, especially with respect to the optimal duration of its use.
authors.affiliation: Center of Oncology, University Hospital Split, Split, Croatia. eduard.vrdoljak@st.t-com.hr
authors.forename: Eduard
authors.initials: E
authors.lastname: Vrdoljak
authors.forename: Branka Petrić
authors.initials: BP
authors.lastname: Mise
authors.forename: Blanka
authors.initials: B
authors.lastname: Lukić
authors.forename: Zvonimir
authors.initials: Z
authors.lastname: Curić
authors.forename: Lidija
authors.initials: L
authors.lastname: Bosković
authors.forename: Ivana
authors.initials: I
authors.lastname: Tica
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D000069287:Capecitabine; D044584:Carcinoma, Ductal / Q000188:drug therapy / Q000235:genetics / Q000556:secondary*; D002291:Carcinoma, Papillary / Q000188:drug therapy / Q000235:genetics / Q000556:secondary*; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D034261:Epothilones / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005500:Follow-Up Studies; D006801:Humans; D008134:Long-Term Care; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000188:drug therapy* / Q000235:genetics; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D011960:Receptors, Estrogen / Q000235:genetics; D011980:Receptors, Progesterone / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; D000069287:Capecitabine; D003841:Deoxycytidine; D034261:Epothilones; D005472:Fluorouracil; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C430592:ixabepilone